by Madaline Spencer | Feb 24, 2025
Alix Arnaud, Director of Health Economic and Value Assessment BP at Sanofi, discusses the cost of efanesoctocog alfa compared with other Factor VIII replacement therapies for major surgeries in patients with hemophilia A. Hemophilia A is an inherited...
by Madaline Spencer | Feb 21, 2025
Kelly Knupp, MD, Pediatric Epileptologist at the University of Colorado, discusses the phase 3 EMPEROR clinical trial for pediatric patients with Dravet syndrome. Dravet syndrome is the most severe of a group of conditions known as SCN1A-related seizure...
by Madaline Spencer | Feb 20, 2025
Jorge Cortes, MD, Director of the Georgia Cancer Center, discusses five year follow-up results of the OPTIC clinical trial for chronic myeloid leukemia (CML). CML is a myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion...
by Madaline Spencer | Feb 19, 2025
Dina Matos, Executive Director of the CARES Foundation, discusses the recent approval of crinecerfont to treat patients with congenital adrenal hyperplasia (CAH) by the U.S. Food and Drug Administration (FDA). CAH refers to a group of genetic conditions...
by Madaline Spencer | Feb 18, 2025
Michael Panzara, MD, Chief Medical Officer at Neurvati Neurosciences and GRIN Therapeutics, discusses topline results of the Honeycomb trial for GRIN-related neurodevelopmental disorder with gain-of-function (GoF) variants. GRIN-related neurodevelopmental...
